Received Jun 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | X011424 | — |
No additional AE; administration of expired VARIVAX to a patient; Information has been received from Business Partner/CRO on 06-Jun-2025. This spontaneous report was received from a/an Physician Assistant and refers to a(n) patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 06-Jun-2025, the patient started therapy with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), Injection (lot #X011424, expiration date: 19-Apr-2025). On 06-Jun-2025, the patient started therapy with sterile diluent (MERCK STERILE DILUENT), (indication, expiration date, and lot # were not reported). The patient started therapy with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), for the treatment of prophylaxis. On 06-Jun-2025, the patient experienced administration of expired VARIVAX to a patient. On an unknown date, the patient experienced No additional AE. At the reporting time, the outcome of administration of expired VARIVAX to a patient and No additional AE was unknown. The action taken with sterile diluent and Varicella Virus Vaccine Live (Oka-Merck) was reported as not applicable.
Merck sterile diluent